ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,837 | -0.9% | 13,467 | +9.8% | 0.01% | 0.0% |
Q1 2024 | $1,854 | +29.5% | 12,267 | +7.9% | 0.01% | +14.3% |
Q4 2023 | $1,432 | +34.6% | 11,367 | 0.0% | 0.01% | +16.7% |
Q3 2023 | $1,064 | +32.5% | 11,367 | +26.3% | 0.01% | +50.0% |
Q2 2023 | $803 | -11.9% | 9,000 | +5.9% | 0.00% | -20.0% |
Q1 2023 | $911 | +5.1% | 8,500 | +19.7% | 0.01% | 0.0% |
Q4 2022 | $867 | -99.9% | 7,100 | -26.0% | 0.01% | -28.6% |
Q3 2022 | $991,000 | +11.1% | 9,600 | 0.0% | 0.01% | +16.7% |
Q2 2022 | $892,000 | -21.6% | 9,600 | -1.0% | 0.01% | 0.0% |
Q1 2022 | $1,138,000 | -12.8% | 9,700 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $1,305,000 | -22.8% | 9,700 | -8.5% | 0.01% | -33.3% |
Q3 2021 | $1,690,000 | +38.2% | 10,600 | +14.0% | 0.01% | +50.0% |
Q2 2021 | $1,223,000 | +2.0% | 9,300 | 0.0% | 0.01% | -14.3% |
Q1 2021 | $1,199,000 | -30.2% | 9,300 | -9.7% | 0.01% | -30.0% |
Q4 2020 | $1,718,000 | +27.9% | 10,300 | +18.4% | 0.01% | 0.0% |
Q3 2020 | $1,343,000 | -47.8% | 8,700 | -50.0% | 0.01% | -9.1% |
Q2 2020 | $2,574,000 | – | 17,400 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |